Videos

Acute Myeloid Leukemia with Myelodysplastic-Related Cytogenetics

Naval G. Daver, MD, discusses how the efficacy compares between first- and second-generation FLT3 inhibitors in acute myeloid leukemia.

Alain Borczuk, MD, discusses the current role for liquid biopsies versus tissue biopsies in lung cancer and the challenges that need to be overcome in this space.

Breast Cancer

Martin E. Gutierrez, MD, director, Drug Discovery/Phase I Unit, and co-chief and medical oncologist, Divisions of Thoracic Oncology and Gastrointestinal Oncology, John Theurer Cancer Center, Hackensack University Medical Center, discusses the early findings for H3B-6527, an FGFR4 inhibitor, as a treatment of patients with hepatocellular carcinoma (HCC) or intrahepatic cholangiocarcinoma

Evan Y. Yu, MD, discussed the key takeaways from the phase Ib/II KEYNOTE-365 trial, which evaluated different novel pembrolizumab (Keytruda) combinations in patients with metastatic castration-resistant prostate cancer.

Charu Aggarwal, MD, MPH, the Leslye M. Heisler Assistant Professor for Lung Cancer Excellence at Perelman School of Medicine, University of Pennsylvania, and other researchers conducted a prospective study using next-generation sequencing as a biomarker to predict response and progression-free survival rates in patients with non–small cell lung cancer  receiving pembrolizumab monotherapy. The data were presented during the 2019 ASCO Annual Meeting.

Ana Oaknin, MD, head of the Gynecologic Tumors Unit, Vall d’Hebron University Hospital, and principal investigator, Gynecological Malignancies Group, explains the rationale for analyzing anti–PD-1 monotherapy with dostarlimab in patients with microsatellite instability–high and microsatellite stable endometrial cancer. 

Karim Fizazi, MD, PhD,head of the Department of Cancer Medicine,&nbsp;Institut Gustave Roussy, University of Paris-Sud, gives highlights on the updated findings from the phase III ARAMIS trial using darolutamide for the treatment of patients with nonmetastatic castration-resistant prostate cancer, recently presented during the 2019 ASCO Annual Meeting.&nbsp;<br /> &nbsp;

Pancreatic cancer with&nbsp;<em>BRCA1</em>and&nbsp;<em>BRCA2&nbsp;</em>mutations has shown positive responses to the PARP inhibitor olaparib in preliminary trials.&nbsp;